291 related articles for article (PubMed ID: 31932172)
1. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
[TBL] [Abstract][Full Text] [Related]
2. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.
Wu CY; Wu CY; Li CP; Chou YJ; Lin YH; Chang YT
Diabetes Res Clin Pract; 2021 Jan; 171():108546. PubMed ID: 33232759
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
Benzaquen M; Borradori L; Berbis P; Cazzaniga S; Valero R; Richard MA; Feldmeyer L
J Am Acad Dermatol; 2018 Jun; 78(6):1090-1096. PubMed ID: 29274348
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
Kawaguchi Y; Shimauchi R; Nishibori N; Kawashima K; Oshitani S; Fujiya A; Shibata T; Ohashi N; Izumi K; Nishie W; Shimizu H; Arima H; Sobajima H
J Diabetes Investig; 2019 Mar; 10(2):392-398. PubMed ID: 29920976
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Hung CT; Liu JS; Cheng CY; Chung CH; Chiang CP; Chien WC; Wang WM
J Dermatol; 2020 Mar; 47(3):245-250. PubMed ID: 31885117
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl-peptidase IV inhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences.
Kridin K
Dermatol Ther; 2020 Jul; 33(4):e13790. PubMed ID: 32506731
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation.
Kridin K; Avni O; Damiani G; Tzur Bitan D; Onn E; Weinstein O; Cohen AD
Arch Dermatol Res; 2023 Jan; 315(1):33-39. PubMed ID: 35032198
[TBL] [Abstract][Full Text] [Related]
8. The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study.
Bukvić Mokos Z; Petković M; Balić A; Marinović B
Croat Med J; 2020 Apr; 61(2):93-99. PubMed ID: 32378375
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
[TBL] [Abstract][Full Text] [Related]
10. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Mai Y; Nishie W; Izumi K; Shimizu H
Front Immunol; 2019; 10():1224. PubMed ID: 31191560
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.
Kim SC; Glynn RJ; Liu J; Everett BM; Goldfine AB
Acta Diabetol; 2014 Dec; 51(6):1015-23. PubMed ID: 25311055
[TBL] [Abstract][Full Text] [Related]
13. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
14. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
[TBL] [Abstract][Full Text] [Related]
15. A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
Sawada K; Sawada T; Kobayashi T; Fujiki A; Matsushita T; Kawara S; Izumi K; Nishie W; Shimizu H; Takehara K; Hamaguchi Y
Immunol Med; 2021 Mar; 44(1):53-55. PubMed ID: 32634333
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Seong JM; Yee J; Gwak HS
Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554
[TBL] [Abstract][Full Text] [Related]
17. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
Dombrowski S; Kostev K; Jacob L
Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
[TBL] [Abstract][Full Text] [Related]
18. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
Front Immunol; 2018; 9():542. PubMed ID: 29706950
[TBL] [Abstract][Full Text] [Related]
19. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
Kridin K; Bergman R
JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
[TBL] [Abstract][Full Text] [Related]
20. Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study.
Varpuluoma O; Försti AK; Jokelainen J; Turpeinen M; Timonen M; Tasanen K; Huilaja L
J Am Acad Dermatol; 2018 Dec; 79(6):1034-1038.e5. PubMed ID: 29803903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
